Taken together, our results indicate that the overexpression of INSL5 promoted chemoresistance to conventional chemotherapy, while anti‐INSL5 or GPCR142 neutralizing antibodies could suppress tumor alone or renders NPC cell sensitive to chemotherapy, revealing a novel strategy for NPC therapy. This evidence concerns the gene RXFP4 and nasopharyngeal carcinoma.